In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe

Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01195-20. doi: 10.1128/AAC.01195-20. Print 2020 Oct 20.

Abstract

Contezolid, a new oxazolidinone antibacterial agent currently in development for the treatment of skin and skin structure infections, was susceptibility tested against Gram-positive clinical isolates (n = 1,211). Contezolid demonstrated potent activity against Staphylococcus aureus (MIC50/90, 0.5/1 mg/liter), coagulase-negative Staphylococcus (MIC50/90, 0.25/0.5 mg/liter), Enterococcus spp. (MIC50/90, 0.5/1 mg/liter), and streptococci (MIC50/90, 1/1 mg/liter). Moreover, methicillin-resistant S. aureus and vancomycin-resistant Enterococcus faecium isolates were all inhibited by contezolid at ≤1 mg/liter. These results support the clinical development of contezolid.

Keywords: Enterococcus; MRSA; Staphylococcus aureus; Streptococcus spp.; antibiotics; streptococci.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Europe
  • Gram-Positive Bacteria
  • Methicillin-Resistant Staphylococcus aureus*
  • Microbial Sensitivity Tests
  • Oxazolidinones* / pharmacology
  • Pyridones
  • United States

Substances

  • Anti-Bacterial Agents
  • Oxazolidinones
  • Pyridones
  • contezolid